Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

S. Feyerabend; N. Shore; M. Smith; E. Kopyltsov; I. Antonyan; J. Damber; D. Gasparro; A. Yildirim; M. Hellstrom; E. Vjaters; J. Ortiz; S. Srinivasan; T. Sarapohja; K. Fizazi

doi:10.1016/S0302-2838(21)01598-0

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

S. Feyerabend
, N. Shore
, M. Smith
, E. Kopyltsov
, I. Antonyan
, J. Damber
, D. Gasparro
, A. Yildirim
, M. Hellstrom
, E. Vjaters
, J. Ortiz
, S. Srinivasan
, T. Sarapohja
, K. Fizazi

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	P1227
Pages (from-to)	S1742-S1743
Number of pages	2
Journal	European Urology
Volume	79
Issue number	Supplement 1
DOIs	https://doi.org/10.1016/S0302-2838(21)01598-0
Publication status	Published - Jun 2021
Externally published	Yes
Event	36th Annual European Association of Urology (EAU) Congress - Virtual Duration: 8 Jul 2021 → 13 Jul 2021 Conference number: 36 https://www.urotoday.com/calendar-events/492.html

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1016/S0302-2838(21)01598-0

https://www.europeanurology.com/article/S0302-2838(21)01598-0/fulltext

Cite this

Feyerabend, S., Shore, N., Smith, M., Kopyltsov, E., Antonyan, I., Damber, J., Gasparro, D., Yildirim, A., Hellstrom, M., Vjaters, E., Ortiz, J., Srinivasan, S., Sarapohja, T., & Fizazi, K. (2021). Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study. European Urology, 79(Supplement 1), S1742-S1743. Article P1227. https://doi.org/10.1016/S0302-2838(21)01598-0

@article{f984c4d81cba4e0b801af349950986d1,

title = "Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study",

author = "S. Feyerabend and N. Shore and M. Smith and E. Kopyltsov and I. Antonyan and J. Damber and D. Gasparro and A. Yildirim and M. Hellstrom and E. Vjaters and J. Ortiz and S. Srinivasan and T. Sarapohja and K. Fizazi",

year = "2021",

month = jun,

doi = "10.1016/S0302-2838(21)01598-0",

language = "English",

volume = "79",

pages = "S1742--S1743",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "Supplement 1",

note = "36th Annual European Association of Urology (EAU) Congress, EAU 2021 ; Conference date: 08-07-2021 Through 13-07-2021",

url = "https://www.urotoday.com/calendar-events/492.html",

}

Feyerabend, S, Shore, N, Smith, M, Kopyltsov, E, Antonyan, I, Damber, J, Gasparro, D, Yildirim, A, Hellstrom, M, Vjaters, E, Ortiz, J, Srinivasan, S, Sarapohja, T & Fizazi, K 2021, 'Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study', European Urology, vol. 79, no. Supplement 1, P1227, pp. S1742-S1743. https://doi.org/10.1016/S0302-2838(21)01598-0

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study. / Feyerabend, S.; Shore, N.; Smith, M. et al.
In: European Urology, Vol. 79, No. Supplement 1, P1227, 06.2021, p. S1742-S1743.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

AU - Feyerabend, S.

AU - Shore, N.

AU - Smith, M.

AU - Kopyltsov, E.

AU - Antonyan, I.

AU - Damber, J.

AU - Gasparro, D.

AU - Yildirim, A.

AU - Hellstrom, M.

AU - Vjaters, E.

AU - Ortiz, J.

AU - Srinivasan, S.

AU - Sarapohja, T.

AU - Fizazi, K.

N1 - Conference code: 36

PY - 2021/6

Y1 - 2021/6

UR - https://www-webofscience-com.db.rsu.lv/wos/woscc/full-record/WOS:000674144301498

U2 - 10.1016/S0302-2838(21)01598-0

DO - 10.1016/S0302-2838(21)01598-0

M3 - Meeting Abstract

SN - 0302-2838

VL - 79

SP - S1742-S1743

JO - European Urology

JF - European Urology

IS - Supplement 1

M1 - P1227

T2 - 36th Annual European Association of Urology (EAU) Congress

Y2 - 8 July 2021 through 13 July 2021

ER -

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this